Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

OBJECTIVES: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. DESIGN: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Int J Infect Dis
Główni autorzy: Generali, Daniele, Bosio, Giancarlo, Malberti, Fabio, Cuzzoli, Antonio, Testa, Sophie, Romanini, Laura, Fioravanti, Antonio, Morandini, Alessandro, Pianta, Luca, Giannotti, Guglielmo, Viola, Erika Maria, Giorgi-Pierfranceschi, Matteo, Foramitti, Marina, Tira, Rosa Angela, Zangrandi, Ilaria, Chiodelli, Giulia, Machiavelli, Andrea, Cappelletti, Maria Rosa, Giossi, Alessia, De Giuli, Valeria, Costanzi, Chiara, Campana, Chiara, Bernocchi, Ottavia, Sirico, Marianna, Zoncada, Alessia, Molteni, Alfredo, Venturini, Sergio, Giudici, Fabiola, Scaltriti, Maurizio, Pan, Angelo
Format: Artigo
Język:Inglês
Wydane: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Hasła przedmiotowe:
Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771302/
https://ncbi.nlm.nih.gov/pubmed/33385581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.12.073
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy